2008年胃肠道神经内分泌肿瘤管理方面的成就。
Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.
作者信息
Kulke Matthew H, Scherübl Hans
机构信息
Dana-Farber Cancer Institute, Boston, MA.
出版信息
Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S62-6.
Abstract
Overview of the Disease ProcessIncidencePrognostic FactorsGeneral Therapy StandardsAccomplishments and Lack of Accomplishments During the YearSomatostatin AnalogsPeptide Receptor-Targeted TherapySelective Internal Radiotherapy (SIRT)CYTOTOXIC THERAPIES: TemozolomideVEGF Pathway InhibitorsmTOR InhibitorsDevelopment of BiomarkersWhat Needs to be Done (Application of the Accomplishments)Controversies and DisagreementsHistologic Classification and Staging of Neuroendocrine TumorsClinical Trial Design and End PointsFuture Directions.
摘要
疾病过程概述
发病率
预后因素
一般治疗标准
年度成就与不足
生长抑素类似物
肽受体靶向治疗
选择性内放射治疗（SIRT）
细胞毒性疗法
替莫唑胺
血管内皮生长因子（VEGF）通路抑制剂
雷帕霉素靶蛋白（mTOR）抑制剂
生物标志物的发展
需要做的事情（成就的应用）
争议与分歧
神经内分泌肿瘤的组织学分类与分期
临床试验设计与终点
未来方向
相似文献
1
Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.
Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S62-6.
2
Accomplishments in 2007 in the adjuvant treatment of colorectal cancer.
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S2-6.
3
Accomplishments in 2007 in the adjuvant treatment of rectal cancer.
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S7-S12.
4
Accomplishments in 2007 in the management of hepatobiliary cancers.
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S25-31.
5
Accomplishments in 2007 in the management of curable metastatic colorectal cancer.
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S13-8.
6
Accomplishments in 2007 in the management of localized pancreatic cancer.
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S32-6.
7
Accomplishments in 2008 in the management of curable metastatic colorectal cancer.
Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S15-22.
8
A descriptive analysis of the characteristics, treatment response and prognosis of hepatic dominant solid tumors undergoing selective internal radiation therapy (SIRT).
J Gastrointest Oncol. 2022 Dec;13(6):3240-3253. doi: 10.21037/jgo-22-122.
9
Accomplishments in 2007 in the treatment of metastatic pancreatic cancer.
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S37-41.
10
ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs).
BMC Cancer. 2022 Jul 20;22(1):800. doi: 10.1186/s12885-022-09859-9.
引用本文的文献
1
Expression Patterns of Immune Checkpoint Molecules and Their Clinical Values in Gastric Neuroendocrine Neoplasms.
Clin Transl Gastroenterol. 2025 Apr 4;16(6):e00842. doi: 10.14309/ctg.0000000000000842. eCollection 2025 Jun 1.
2
Systemic treatment for lung carcinoids: from bench to bedside.
Clin Transl Med. 2019 Jul 4;8(1):22. doi: 10.1186/s40169-019-0238-5.
3
Neuroendocrine Tumors of the Esophagus: State of the Art in Diagnostic and Therapeutic Management.
J Gastrointest Cancer. 2017 Dec;48(4):299-304. doi: 10.1007/s12029-017-9978-x.
4
Multidisciplinary management of advanced lung neuroendocrine tumors.
J Thorac Dis. 2015 Apr;7(Suppl 2):S163-71. doi: 10.3978/j.issn.2072-1439.2015.04.20.
5
Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptor.
Biochim Biophys Acta. 2013 Mar;1833(3):573-82. doi: 10.1016/j.bbamcr.2012.11.021. Epub 2012 Dec 4.
6
Endoscopic ultrasound in gastroenteropancreatic neuroendocrine tumors.
Gut Liver. 2012 Oct;6(4):405-10. doi: 10.5009/gnl.2012.6.4.405. Epub 2012 Aug 7.
7
Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study.
World J Gastroenterol. 2012 Oct 28;18(40):5799-806. doi: 10.3748/wjg.v18.i40.5799.
8
Signaling mechanisms in neuroendocrine tumors as targets for therapy.
Endocrinol Metab Clin North Am. 2010 Dec;39(4):801-10. doi: 10.1016/j.ecl.2010.08.002.
本文引用的文献
1
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Clin Cancer Res. 2009 Jan 1;15(1):338-45. doi: 10.1158/1078-0432.CCR-08-1476.
2
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.
J Natl Cancer Inst. 2008 Sep 17;100(18):1282-9. doi: 10.1093/jnci/djn275. Epub 2008 Sep 9.
3
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.
J Clin Oncol. 2008 Sep 10;26(26):4311-8. doi: 10.1200/JCO.2008.16.7858.
4
Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.
Cancer. 2008 Aug 15;113(4):690-700. doi: 10.1002/cncr.23700.
5
Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
Cancer. 2008 Sep 1;113(5):921-9. doi: 10.1002/cncr.23685.
6
Activity of sunitinib in patients with advanced neuroendocrine tumors.
J Clin Oncol. 2008 Jul 10;26(20):3403-10. doi: 10.1200/JCO.2007.15.9020.
7
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377.
8
Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
Am J Clin Oncol. 2008 Jun;31(3):271-9. doi: 10.1097/COC.0b013e31815e4557.
9
Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study.
Int J Cancer. 2008 Aug 15;123(4):867-73. doi: 10.1002/ijc.23529.
10
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
J Clin Oncol. 2008 May 1;26(13):2124-30. doi: 10.1200/JCO.2007.15.2553.
Zotero 插件